Neonatal drug development

descriptionPublicationkeyboard_double_arrow_right Article 01 Nov 2011 English Publisher:Elsevier BVJournal:Early Human Development, volume 87, pages 763-768 (issn: 0378-3782,

Copyright policy )

Authors: Mark A, Turner;

doi: 10.1016/j.earlhumdev.2011.08.014

pmid: 21925812

Neonatal drug development

- Summary
- Subjects
- Metrics

Abstract

Drug development is crucial to improving the care given to neonates through new and existing medicines. Pressure from regulatory agencies has improved the way in which pharmaceutical companies work with neonates. This provides new opportunities for the neonatal community. This paper describes the issues that arise during the development of new drugs and considers how the contemporary approach to new drugs can inform research on existing drugs.

Related Organizations

University of Liverpool
United Kingdom

Keywords

Marketing of Health Services, Drug Industry, Pharmaceutical Preparations, Research Design, Drug Design, Infant, Newborn, Drug Evaluation, Humans, Drug Tolerance, Biomarkers

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	26
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%